The role of quetiapine extended release in the treatment of bipolar depression

Advances in Therapy

Volumn 27, Issue 11, 2010, Pages 774-784

  Cristancho, Mario A ^a   Thase, Michael E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adherence; Bioequivalence; Bipolar depression; Effectiveness; Quetiapine; Safety

Indexed keywords

NEUROLEPTIC AGENT; PAROXETINE; PLACEBO; QUETIAPINE;

ANXIETY DISORDER; AREA UNDER THE CURVE; BEDTIME DOSAGE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HUMAN; INCREASED APPETITE; MAJOR DEPRESSION; MANIA; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DELAYED-ACTION PREPARATIONS; DIBENZOTHIAZEPINES; DRUG TOXICITY; HUMANS; MEDICATION ADHERENCE; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 78649325565     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-010-0067-9     Document Type: Review

References (44)

1. Kraepelin E. Manic-Depressive Insanity and Paranois. Manchester, NH: Ayer Company Publishers; 1921.
2. American Psychiatric Association: Diagnostic and Statistical manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
3. P. Keck R. McIntyre R. Shelton 2007 Bipolar depression: best practices for the outpatient CNS Spectr 12 suppl.20 1 16
4. L. Judd H. Akishal P. Schettler 2002 The long-term natural history of the weekly symptomatic status of bipolar I disorder Arch Gen Psychiatry 59 530 537 10.1001/archpsyc.59.6.530 12044195
5. L. Judd H. Akishal P. Schettler 2003 A prospective investigation of the natural history of the long term weekly symptomatic status of bipolar II disorder Arch Gen Psychiatry 60 261 269 10.1001/archpsyc.60.3.261 12622659 (Pubitemid 36307437)
6. M. Thase 2008 Quetiapine monotherapy for bipolar depression Neuropsych Dis Treat 4 21 31 1:CAS:528:DC%2BD1cXkvVeis7Y%3D
7. R. Hirschfeld 2004 Bipolar depression: the real challenge Eur Neuropsychopharmacol 14 suppl.2 S83 S88 1:CAS:528:DC%2BD2cXktVClu7c%3D 10.1016/j.euroneuro.2004.03.001 15142612 (Pubitemid 38610216)
8. L. Judd H. Akishal P. Schettler 2005 Psychosocial disability in the course of bipolar I and II disorder: a prospective, comparative, longitudinal study Arch Gen Psychiatry 62 1322 1330 10.1001/archpsyc.62.12.1322 16330720 (Pubitemid 41746610)
9. S. Disalver Y. Chen A. Swann 1997 Suicidality, panic disorder and psychosis in bipolar depression, depressive mania and pure mania Psychiatry Res 73 47 56 10.1016/S0165-1781(97)00109-1 (Pubitemid 28032207)
10. A. Fagiolini E. Frank J. Scott 2005 Metabolic syndrome in bipolar disorder: findings from the bipolar disorders center for Pennsylvanians Bipolar Disord 7 424 430 10.1111/j.1399-5618.2005.00234.x 16176435 (Pubitemid 41419409)
11. P. Mitchell G. Malhi 2004 Bipolar depression: phenomenological overview and clinical characteristics Bipolar Disord 5 530 539 10.1111/j.1399-5618.2004. 00137.x (Pubitemid 39562421)
12. M. Thase T. Denko 2008 Pharmacotherapy of mood disorders Annu Rev Clin Psychol 4 53 91 10.1146/annurev.clinpsy.2.022305.095301 18370614 (Pubitemid 351668611)
13. J. Calabrese P. Keck W. Macfadden 2005 A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression Am J Psychiatry 162 1351 1360 10.1176/appi.ajp.162.7.1351 15994719 (Pubitemid 40905587)
14. E. Brown S. McElroy P. Keck 2006 A 7-week randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression J Clin Psychiatry 67 1025 1033 1:CAS:528: DC%2BD28XoslGis7o%3D 10.4088/JCP.v67n0703 16889444 (Pubitemid 44230872)
15. J. Calabrese C. Bowden G. Sachs 1999 A double-blind placebo controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group J Clin Psychiatry 60 79 88 1:CAS:528:DyaK1MXhvVSitbc%3D 10.4088/JCP.v60n0203 10084633
16. M. Tohen E. Vieta J. Calabrese 2003 Efficacy of olanzapine and olanzapine - fluoxetine combination in the treatment of bipolar I depression Arch Gen Psychiatry 11 1079 1088 10.1001/archpsyc.60.11.1079 (Pubitemid 37429647)
17. M. Thase W. MacFadden R. Weisler 2006 Efficacy of quetiapine monotherapy in bipolar I and II depression: a double blind, placebo controlled study (the BOLDER II study) J Clin Psychopharmacol 26 600 609 1:CAS:528:DC%2BD28Xht1Smt7jE 10.1097/01.jcp.0000248603.76231.b7 17110817 (Pubitemid 44772737)
18. T. Suppes R.M. Hirschfeld E. Vieta 2008 Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies World J Biol Psychiatry 9 198 211 10.1080/15622970701317265 17853277
19. T. Suppes C. Datto M. Minkwitz 2010 Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression J Affect Dis 121 106 115 1:CAS:528:DC%2BD1MXhs1Wgu7nP 10.1016/j.jad.2009.10.007 19903574
20. E.L. Altschuler R.E. Kast 2005 Using histamine (H1) antagonists, in particular atypical antipsychotics to treat anemia of chronic disease via interleukin-6 suppression Med Hypoth 65 65 67 1:CAS:528:DC%2BD2MXktVOkt7k%3D 10.1016/j.mehy.2005.01.036 (Pubitemid 40704532)
21. N. Simon M. Otto S. Wisniewski 2004 Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) Am J Psychiatry 161 2222 2229 10.1176/appi.ajp.161.12.2222 15569893 (Pubitemid 39587287)
22. N. Simon M. Otto R. Weiss 2004 Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD J Clin Psychopharmacol 24 512 520 1:CAS:528:DC%2BD2cXnt1Oqs74%3D 10.1097/01.jcp.0000138772.40515.70 15349007 (Pubitemid 39274205)
23. J. Fawcett 2001 Treating impulsivity and anxiety in the suicidal patient Ann NY Acad Sci 932 94 102 1:STN:280:DC%2BD3MzkvVGmtw%3D%3D 10.1111/j.1749-6632. 2001.tb05800.x 11411193
24. E. Frank J. Cyranowski P. Rucci 2002 Clinical significance of lifetime panic spectrum symptoms in the treatment of patients with bipolar I disorder Arch Gen Psychiatry 59 905 911 10.1001/archpsyc.59.10.905 12365877
25. B. Gaudiano I. Miller 2005 Anxiety disorder comorbidity in bipolar I disorder: relationship to depression severity and treatment outcome Depress Anxiety 21 71 77 10.1002/da.20053 15786484 (Pubitemid 40734022)
26. R.M. Hirschfeld R.H. Weisler S.R. Raines 2006 Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study J Clin Psychiatry 67 355 362 1:CAS:528:DC%2BD28Xkt1KmsL4%3D 10.4088/JCP.v67n0304 16649820
27. B. Bandelow G. Chouinard J. Bobes 2010 Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, doubleblind, placebo-and active-controlled study Int J Neuropsychopharmacol 13 305 320 1:CAS:528:DC%2BC3cXjvVKns7c%3D 10.1017/S1461145709990423 19691907
28. R. Kahn C. Schulz V. Palazov 2007 Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study J Clin Psychiatry 68 832 842 1:CAS:528:DC%2BD2sXot1eitrk%3D 10.4088/JCP.v68n0603 17592906
29. R. Weisler M. Joyce L. McGill 2009 Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study CNS Spectr 14 299 313 19668121
30. C. Figueroa M. Brecher J. Hamer-Maansson 2009 Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine inmediate release Prog Neuropsychopharmacol Biol Psychiatry 33 199 204 1:CAS:528: DC%2BD1MXit1Wqtb8%3D 10.1016/j.pnpbp.2008.09.026 18948162
31. M. Thase 2005 Bipolar depression: issues in diagnosis and treatment Harv Rev Psychiatry 13 257 271 10.1080/10673220500326425 16251165 (Pubitemid 41540947)
32. L. Yatham S. Kennedy C. O'Donovan 2006 Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007 Bipolar Disord 8 721 739 1:CAS:528: DC%2BD2sXht1Shtrs%3D 10.1111/j.1399-5618.2006.00432.x 17156158 (Pubitemid 44824712)
33. J. Golberg C. Truman 2003 Antidepressant-induced mania: an overview of current controversies Bipolar Disord 5 407 420 10.1046/j.1399-5618.2003.00067.x (Pubitemid 38072243)
34. E. Vieta 2005 Mood stabilization in the treatment of bipolar disorder: focus on quetiapine Hum Psychopharmacol 20 225 236 1:CAS:528: DC%2BD2MXmt1Clsr8%3D 10.1002/hup.689 15880391 (Pubitemid 40873460)
35. G. Sachs 2005 What is a mood stabilizer Clin Appr Bipolar Disorder 4 3
36. C. Schneck 2006 Treatment of rapid cycling bipolar disorder J Clin Psychiatry 67 suppl.11 22 27 1:CAS:528:DC%2BD28XhtVOgtbzL 17029493
37. Seroquel XR (quetiapine fumarate) extended-release tablets. Highlights of prescribing information. Available at: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/ UCM191895.pdf. Accessed April 30, 2010.
38. N.H. Jensen R.M. Rodriguiz M.G. Caron 2008 N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity Neuropsychopharmacol 33 2303 23012 1:CAS:528:DC%2BD1cXpslSisbs%3D 10.1038/sj.npp.1301646
39. R.K. Al Jurdi L.A. Dixit M. Sajatovic 2010 Role of extended release quetiapine in the management of bipolar disorders Neuropsychiatr Dis Treat 6 29 35 1:CAS:528:DC%2BC3cXisVCqtbw%3D 10.2147/NDT.S4903 20361059
40. J. Licinio M.L. Wong 1999 The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection Mol Psychiatry 4 317 327 1:CAS:528:DC%2BD3cXlvVWlu7k%3D 10.1038/sj.mp.4000586 10483047
41. D. Mamo H. Uchida I. Vitcu 2008 Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study J Clin Psychiatry 69 81 86 1:CAS:528:DC%2BD1cXivVOksrY%3D 10.4088/JCP.v69n0111 18312041
42. F. Gianfrancesco K. Rajagopalan M. Sajatovic 2006 Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics J Clin Psychiatry 67 222 232 1:CAS:528:DC%2BD28XjsFOmu7c%3D 10.4088/JCP.v67n0208 16566617 (Pubitemid 43357468)
43. B. Bloom 2001 Daily regimen and compliance with treatment BMJ 323 647 1:STN:280:DC%2BD3MrhvFCjtA%3D%3D 10.1136/bmj.323.7314.647 11566816
44. E. Vieta J. Mullen M. Brecher 2005 Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double blind, randomized, placebo-controlled studies Curr Med Res Opin 21 923 934 1:CAS:528:DC%2BD2MXmslCjsbk%3D 10.1185/030079905X46340 15969892 (Pubitemid 40896240)